Expression of AR-V7 and ARv^567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.

ABSTRACT:

Purpose

Biomarkers aiding treatment optimization in metastatic castration-resistant prostate cancer (mCRPC) are scarce. The presence or absence of androgen receptor (AR) splice variants, AR-V7 and AR^v567es, in mCRPC patient circulating tumor cells (CTC) may be associated with taxane treatment outcomes.Experimental Design: A novel digital droplet PCR (ddPCR) assay assessed AR-splice variant expression in CTCs from patients receiving docetaxel or cabazitaxel in TAXYNERGY (NCT01718353). Patient outcomes were examined according to AR-splice variant expression, including prostate-specific antigen (PSA)₅₀ response and progression-free survival (PFS).

Results

Of the 54 evaluable patients, 36 (67%) were AR-V7⁺, 42 (78%) were AR^v567es+

SUBMITTER: Tagawa ST 

PROVIDER: S-EPMC6432911 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature